Outlook Therapeutics

Update in progress

OTLK (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on monoclonal antibodies for ophthalmic indications. Its lead candidate, ONS-5010, is an ophthalmic bevacizumab formulation in Phase III for wet age-related macular degeneration and other retinal diseases. The company has a collaboration with Cencora. It was formerly Oncobiologics, renamed in 2018, and was incorporated in 2010 in Iselin, New Jersey.

Company score

Sentiment: 0.43; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.31; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive